Related Experiment Video
Updated: Jun 6, 2025
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.5K
Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors as Novel Anticancer
Lara Johanna Friedrich1, Axel Guthart1, Min Zhou1
1Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, 55128 Mainz, Germany.
International Journal of Molecular Sciences
|November 27, 2024
Summary
Researchers discovered compound 4, a novel DNA methyltransferase 1 (DNMT1) inhibitor, that shows significant anticancer activity by suppressing tumor cell growth, migration, and inducing apoptosis.
Area of Science:
- Epigenetics
- Cancer Therapeutics
- Drug Discovery
Background:
- Epigenetic modifications, specifically DNA methylation, play a crucial role in cancer development.
- DNA methyltransferases (DNMTs) are key enzymes in this process, and their inhibition is a promising cancer treatment strategy.
- DNMT1 is frequently overactive in various cancers, making it a prime target for novel anti-cancer drugs.
Purpose of the Study:
- To identify novel hypomethylation agents targeting DNMT1 using virtual screening and molecular docking.
- To evaluate the anti-tumor activity of promising candidate compounds in vitro.
- To characterize the mechanism of action of the most effective compound.
Main Methods:
- Virtual screening of over 11,000 ligands from the ZINC15 database.
- Molecular docking to predict binding affinity to DNMT1.
- In silico and in vitro testing of candidate compounds for DNMT1 inhibition.
- Cell-based assays including proliferation, wound healing, cell cycle, and apoptosis analyses.
Main Results:
- Compound 4 demonstrated potent DNMT1 inhibitory activity.
- Compound 4 effectively inhibited the growth of multiple cancer cell lines.
- Compound 4 induced hypomethylation of the luciferase gene, suppressed cell migration, arrested cell cycle, and promoted apoptosis.
Conclusions:
- Compound 4 is identified as a novel DNMT1 inhibitor with significant anti-cancer properties.
- This study highlights the potential of compound 4 as a therapeutic agent for cancer treatment.
- Further investigation into compound 4's efficacy and safety is warranted.
